Insurance coverage for post-stroke cell therapy is virtually non-existent globally. US Medicare and commercial insurance do not reimburse. European insurance schemes (Spain, Portugal, occasionally Germany) selectively cover for severe, chronic stroke disability refractory to conventional rehabilitation when the patient meets strict medical necessity criteria. Out-of-pocket payment is standard; most families self-fund or enrol in sponsored trials.
Stroke recovery cell therapy ranges from €6,000–8,500 per protocol in specialised neurorehabilitation centres. Intravenous MSC infusion (€6,000–7,000) is most accessible. Intra-arterial delivery via neuroradiology (€7,500–8,500) reaches lesions more directly but requires specialist infrastructure. Neurogenic cell infusions are priced similarly (€6,500–8,000). Most protocols involve 1–2 infusions over 3–6 months, though multi-dose regimens are emerging. Insurance coverage is extremely rare globally; only a few European countries (Spain, Portugal) occasionally reimburse under compassionate frameworks for severe, chronic disability.
Am I a candidate? → · Stroke Recovery: full overview → · Stroke Recovery cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite